​​​
  1. Aurobindo Pharma gets USFDA nod for generic migraine drug

Aurobindo Pharma gets USFDA nod for generic migraine drug

Aurobindo Pharma has received approval from the US health regulator to sell generic Zolmitriptan tablets, a drug used to treat migraine, in the American market.

By: | New Delhi | Published: May 13, 2016 3:17 PM
Aurobindo Pharma Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets in strengths of 2.5 mg and 5 mg. (Photo: Reuters)

Aurobindo Pharma has received approval from the US health regulator to sell generic Zolmitriptan tablets, a drug used to treat migraine, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets in strengths of 2.5 mg and 5 mg, Aurobindo Pharma said in a regulatory filing.

“This product is expected to be launched in second quarter of FY16-17,” it added.

The company’s product is the generic equivalent of IPR Pharmaceuticals’ Zomig, which is used in the treatment of migraine in adults.

“The approved product has an estimated market size of $46.7 million for the 12 months ending March 2016 according to IMS,” Aurobindo Pharma said.

With this approval, the company has now a total of 260 abbreviated new drug application (ANDA) approvals from the USFDA.

Aurobindo shares were trading at Rs 789.45 on BSE, down 1.48 per cent from the previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top